Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
January 13, 2022 18:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its...
New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation
December 13, 2021 09:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating the...
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 12, 2021 07:00 ET
|
Corvus Pharmaceuticals, Inc.
Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy Corvus enrolling additional...
Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 10, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies...
Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 02, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its...
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
November 01, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial...
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
October 27, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by...
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
September 22, 2021 06:00 ET
|
Corvus Pharmaceuticals, Inc.
Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab...
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
September 07, 2021 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will...
Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China
August 16, 2021 17:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that an IND application submitted by...